Sugi Predict

Sugi Predict / Compounds / SCHEMBL161850

SCHEMBL161850

SCHEMBL161850

NC(=O)c1cccc(Br)c1N

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ METAP2 P50579 1/20 0.47
▸ KDM4E B2RXH2 2/20 0.45
▸ ALDH1A1 P00352 2/20 0.45
▸ MAPT P10636 1/20 0.45
▸ HPGD P15428 1/20 0.45
▸ TSHR P16473 1/20 0.45
▸ HSD17B10 Q99714 1/20 0.45
▸ GAA P10253 1/20 0.41
▸ PARP1 P09874 5/20 0.41
▸ G6PD P11413 1/20 0.41
▸ CASP7 P55210 1/20 0.41
▸ CASP6 P55212 1/20 0.41
▸ BCAT2 O15382 1/20 0.41
▸ KEAP1 Q14145 1/20 0.40
▸ NFE2L2 Q16236 1/20 0.40
▸ PDPK1 O15530 1/20 0.40
▸ ERN1 O75460 1/20 0.39
▸ CD38 P28907 1/20 0.39
▸ DGAT1 O75907 1/20 0.38
▸ PRNP P04156 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL40536 0.84 ALDH1A1 (0.54) METAP2KDM4EALDH1A1MAPTHPGD
SCHEMBL162974 0.83 G6PD (0.61) KDM4EALDH1A1MAPTHPGDTSHR
SCHEMBL31003730 0.83 G6PD (0.61) KDM4EALDH1A1MAPTHPGDTSHR
SCHEMBL1188598 0.81 G6PD (0.39) ALDH1A1MAPTHPGDHSD17B10GAA
SCHEMBL3170417 0.80 METAP2 (0.48) METAP2KDM4EALDH1A1MAPTHPGD
SCHEMBL700922 0.79 METAP2 (0.58) METAP2KDM4EALDH1A1MAPTHPGD
SCHEMBL1996333 0.78 ERN1 (0.52) METAP2KDM4EALDH1A1MAPTHPGD
SCHEMBL11822135 0.78 L3MBTL1 (0.39) ALDH1A1MAPTHSD17B10G6PDCASP7
SCHEMBL5072449 0.78 METAP2 (0.47) METAP2KDM4EALDH1A1MAPTHPGD
SCHEMBL31700607 0.78 ERN1 (0.52) METAP2KDM4EALDH1A1MAPTHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117820337-A Preparation method of 12H-benzo [4,5] thiazolo [2,3-b ] quinazoline 12-ketone compound 赣南师范大学 2024-04-05 — — CN claimed
CN-120192270-A Polysubstituted benzamide compound, preparation method, application and pharmaceutical composition thereof 中国医学科学院药物研究所 2025-06-24 — — CN disclosed
WO-2024099269-A1 ARYLAMIDE COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, USE THEREOF 华东师范大学 2024-05-16 — — WO disclosed
CN-118026880-A Aryl amide compound, pharmaceutical composition containing same and application thereof 华东师范大学 2024-05-14 — — CN disclosed
CN-117820337-A Preparation method of 12H-benzo [4,5] thiazolo [2,3-b ] quinazoline 12-ketone compound 赣南师范大学 2024-04-05 — — CN disclosed
CN-113354592-B 2-thioquinazolinone compound and preparation method and application thereof 赣南师范大学 2022-06-21 — — CN disclosed
CN-113354592-A 2-thioquinazolinone compound and preparation method and application thereof 赣南师范大学 2021-09-07 — — CN disclosed
CN-108084104-A 1,2,3- phentriazine -4（3H）The synthetic method of -one compound 温州大学 2018-05-29 — — CN disclosed
US-20160168140-A1 HETEROCYCLIC COMPOUNDS AS ANTIBIOTIC POTENTIATORS SYNERECA PHARMACEUTICALS (US) 2016-06-16 — — US disclosed
WO-2016094730-A1 HETEROCYCLIC COMPOUNDS AS ANTIBIOTIC POTENTIATORS SYNERECA PHARMACEUTICALS, INC. (US) 2016-06-16 — — WO disclosed
CN-103298805-A Quinazoline compounds and methods of use thereof AMBIT BIOSCIENCES CORP 2013-09-11 — — CN disclosed
EP-2611789-A1 QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF Ambit Biosciences Corporation (US) 2013-07-10 — — EP disclosed
WO-2012030948-A1 QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF AMBIT BIOSCIENCES CORPORATION (US) 2012-03-08 — — WO disclosed
US-20120053174-A1 QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF AMBIT BIOSCIENCES CORPORATION 2012-03-01 — — US disclosed
US-20040176361-A1 Fused heterocyclic compound and medicinal use thereof MITSUBISHI PHARMA CORPORATION (JP) 2004-09-09 — — US disclosed
US-20040077667-A1 Quinazolinone derivatives FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-04-22 — — US disclosed
CN-1489581-A Quinazolinone derivatives ����ҩƷ��ҵ��ʽ���� 2004-04-14 — — CN disclosed
EP-1396488-A1 FUSED HETEROCYCLIC COMPOUND AND MEDICINAL USE THEREOF Mitsubishi Pharma Corporation (JP) 2004-03-10 — — EP disclosed
EP-1355888-A1 QUINAZOLINONE DERIVATIVES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2003-10-29 — — EP disclosed
WO-2002048117-A1 QUINAZOLINONE DERIVATIVES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-06-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120053174-A1 QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF JAK3, JAK2, TYK2 METAP2 2887/4885KDM4E 1840/4885ALDH1A1 4588/4885
US-20160168140-A1 HETEROCYCLIC COMPOUNDS AS ANTIBIOTIC POTENTIATORS FOS, FOSB, YAP1 METAP2 3484/4885KDM4E 4525/4885ALDH1A1 4840/4885
US-20040176361-A1 Fused heterocyclic compound and medicinal use thereof PARP11, PARP1, CD38 METAP2 3304/4885KDM4E 2586/4885ALDH1A1 65/4885
US-20040077667-A1 Quinazolinone derivatives PARP1, PARP9, PARP2 METAP2 2877/4885KDM4E 869/4885ALDH1A1 201/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.